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A B S T R A C T
Inhibitors against Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) and B2 (TbrPDEB2) have gained in-
terest as new treatments for human African trypanosomiasis. The recently reported alkynamide tetra-
hydrophthalazinones, which show submicromolar activities against TbrPDEB1 and anti-T. brucei activity, have
been used as starting point for the discovery of new TbrPDEB1 inhibitors. Structure-based design indicated that
the alkynamide-nitrogen atom can be readily decorated, leading to the discovery of 37, a potent TbrPDEB1
inhibitor with submicromolar activities against T. brucei parasites. Furthermore, 37 is more potent against
TbrPDEB1 than hPDE4 and shows no cytotoxicity on human MRC-5 cells. The crystal structures of the catalytic
domain of TbrPDEB1 co-crystalized with several different alkynamides show a bidentate interaction with key-
residue Gln874, but no interaction with the parasite-specific P-pocket, despite being (uniquely) a more potent
inhibitor for the parasite PDE. Incubation of blood stream form trypanosomes by 37 increases intracellular cAMP
levels and results in the distortion of the cell cycle and cell death, validating phosphodiesterase inhibition as
mode of action.
1. Introduction
The two causative agents of human African trypanosomiasis (HAT),
i.e. Trypanosoma brucei (T.b.) rhodesiense and T.b. gambiense are endemic
in sub-Saharan Africa.1,2 The drugs against HAT currently available on
the market have major disadvantages, including limited clinical efficacy
in certain disease stages, complex administration protocols and toxi-
city.1,3–5 Additionally, the small repertoire of available drugs against
HAT suffers from emerging drug resistance.6–10 While the number of
new HAT cases has dropped considerably in the last few years,11 there
remains an interest in developing novel and non-toxic trypanocidal
agents.6–10 Several enzymes have been identified as potential targets for
development of such new treatments.12–16 For example, T. brucei 3′5′-
cyclic nucleotide phosphodiesterase B1 and B2 (TbrPDEB1 and
TbrPDEB2) have been validated as essential enzymes of the parasite and
can be exploited as a drug target.16,17 The high sequence homology
(88%) between the catalytic sites of the TbrPDEB1 and B2 creates a
high degree of equipotency against the paralogues.17–19 However, se-
lectivity for the parasite PDE over the human orthologues, especially
human PDE4 (hPDE4), is required to limit unwanted side effects (e.g.
emesis, gastrointestinal disturbance and immune suppression).19–23
Over the years, several studies reported different hPDE4 inhibitors
as starting point for TbrPDEB1 inhibitors, resulting in a number of
potent inhibitors, e.g. cilomilast analogue 2 and rolipram analogue 4
(Fig. 1).19,24 However, selectivity for TbrPDEB1 over hPDE4 in com-
bination with antiparasitic activity has been a challenge.19,24
Recently, we have shown that the activity profile for TbrPDEB1 over
hPDE4 can be obtained by targeting a parasite-specific P-pocket present
near the active site of TbrPDEB1.25,26 Biphenyl tetra-
hydrophthalazinone NPD-008 (5) (Fig. 2) exhibits a submicromolar
potency for TbrPDEB1 (pKi= 7.0) and a 10-fold selectivity over hPDE4
(pKi= 6.0).25 The crystal structure of 5 (PDB: 5G2B) in the catalytic
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domain of TbrPDEB1 shows that the glycinamide tail occupies the P-
pocket thereby explaining the observed selectivity for TbrPDEB1 over
hPDE4 (Fig. 2).25 Successful targeting of the P-pocket was also observed
in the crystal structure of TbrPDEB1 co-crystallized with NPD-937 (6,
PDB: 5L8Y), indicating that a longer and more spacious tail group is
also able to enter the P-pocket resulting in selectivity for TbrPDEB1
over hPDE4 (TbrPDEB1 pKi= 6.4 vs hPDE4 pKi= 5.5).25 However, 5
and 6 show an unfortunate reduced phenotypic activity against T. brucei
(pIC50= 5.3 and pIC50= 5.1, respectively), thereby halting further
development of these compounds as trypanocidals.25 Further research
to replace the phenyl linker and tail group of 5 by an alkynamide re-
sulted in the discovery of NPD-048 (7) which displays a submicromolar
potency against TbrPDEB1 (TbrPDEB1 pKi= 6.2).27 Although this al-
kynamide does not show a similar activity profile (hPDE4 pKi= 6.5) as
observed with 5, the phenotypic activity against T. brucei (pIC50= 6.0)
improved considerably compared with 5. Moreover, the co-crystal
structure of 7 (PDB: 6FTM) in the catalytic domain of TbrPDEB1 in-
dicates that the scaffold forms a good bidentate interaction with the
conserved glutamine residue Gln874 while the alkynamide nitrogen
atom offers a promising vector to grow the compound towards the P-
pocket.27
Herein, we report the structure-based design of new alkynamide
tetrahydrophthalazinones with different amide substituents in an
attempt to obtain ligands with a better antiparasitic activity.
2. Results and discussion
2.1. In silico exploration of the amide vector
The crystal structures of TbrPDEB1 ligated with 5, 6 and 7 (PDB-
codes 5G2B, 5L8Y, and 6FTM respectively)25,27 were used to explore
suitable amines to decorate the scaffold of 7 to fit the vector towards
the P-pocket described by the alkynamide. All three crystal structures
were used as basis because the P-pocket volume varies, indicating the
flexibility of the P-pocket residues. Reaxys was used to extract all
commercially available (eMolecules) primary or secondary amines with
a molecular mass below 158 Da. Using the combinatorial library module
of Molecular Operating Environment (MOE) software package of Che-
mical Computing Group, the amines were virtually coupled to the al-
kyne tetrahydrophthalazinone scaffold to make a combinatorial library
consisting of 16,153 substituted alkynamides. These molecules were
docked using PLANTS28 into each of the three aforementioned
TbrPDEB1 structures and all resulting docking poses were scored using
Interaction Fingerprints29 (IFP) for the core scaffold of the molecules.
After applying combined scoring cut-offs30 (PLANTS≤−90 and
IFP≥0.5) and filtering for binding poses in which the ligand was in
contact with Gln874, there were 2291 unique molecules left. The
docking results of the 3 different crystal structures were compared and
the overlapping hits were visually inspected (see Fig. 3A). Six com-
pounds, consisting of aliphatic and aromatic substitutions of variating
complexity, were hits in all three sets of docking results (Fig. 3B).
Compounds with a second (primary or secondary) amine or additional
chiral centre were removed from the results to increase synthetic fea-
sibility and to eliminate compounds with more than two diastereomers,
nominating only 11 and 12 for synthesis. Non-chiral amines that were
hits in two of the three sets of docking results (88 compounds) con-
tained a higher abundancy of aromatic tail groups (66%) versus ali-
phatic tail groups (33%), thereby predicting a better occupancy of the
P-pocket by aromatic groups than aliphatic groups. Most amines con-
tained a second heteroatom that can function as a hydrogen bond ac-
ceptor, but no clear preference for flexible or (ring) strained amines was
observed. These results were used as inspiration for the compounds
synthesized from readily available amines.
Fig. 1. Repurposing hPDE4 inhibitors for the development of potent TbrPDEB1
inhibitors for the treatment of human African trypanosomiasis.19,24
Fig. 2. The structures of the reported tetrahydrophthalazinone-based TbrPDEB1 inhibitors with a phenylamide (5 and 6) or alkynamide linker (7) and their binding
pose in the catalytic domain of TbrPDEB1. Key active site residues and the P-pocket are shown for clarity. NPD-008 (5) is displayed in blue, NPD-937 (6) in cyan and
NPD-048 (7) in orange.
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2.2. Chemistry
The previously reported synthetic pathway towards phthalazinone
alkynamides contained several steps with low yield and long reaction
times.25,27 Revision of these steps resulted in the design of a new syn-
thetic route (Scheme 1) with reduced reaction times, easier purifica-
tions and improved yields. In this new scheme 2-bromoanisole was used
in a Friedel-Craft acylation with maleic anhydride to obtain carboxylic
acid 14 in good yield. The conversion towards the E-isomer was also
reported by Onoue et al.31 and confirmed by NMR based on the 3J-
coupling constant of 15.4 Hz between the vinylic hydrogens, typical for
trans alkene protons. The cyclohexene moiety was introduced by a
Diels-Alder reaction with butadiene to form carboxylic acid 15 in
quantitative yield. The subsequent condensation with hydrazine and
alkylation with isopropylbromide was performed as reported pre-
viously.25,27 It was decided to install an isopropyl group instead of a
cycloheptyl substituent of the phthalazinone scaffold for this series of
alkynamides, as this modification has been shown to yield a small po-
sitive effect on the activity profile.25,27 Conversion of the stereo-
chemical configuration from the trans-cyclohexene to the cis-cyclo-
hexene occurs under strongly basic conditions. Comparison of the NMR-
spectra of trans-tetrahydrophthalazinone 16 with the cis-tetra-
hydrophthalazinone synthesized according to previous reported
methods25 showed distinct differences in shift of aromatic protons
(spectra in Supporting Info).
Alkylation of 16 with excess of sodium hydride resulted in a fast
conversion towards the cis-tetrahydrophthalazinone, which was con-
firmed by nuclear magnetic resonance (NMR) spectroscopy using
Nuclear Overhauser Enhancement (NOE) experiments. Upon saturation
of the signal of proton H4a in 15 and 16, a weak NOE correlation with
H8a was observed in the NOE difference spectrum. Saturation of the
signal of proton H4a in 17 resulted in a strong NOE correlation with
H8a and thereby confirming the cis-configuration of 17 (spectra in
Supporting Info). Furthermore, the observed 3J-values of H4a are in
agreement with the trans-isomer for 16 with one small and two large
coupling constants (3J=14.6, 11.4 and 5.4 Hz), indicating one axial-
equatorial and two axial-axial positioned protons.32 The opposite was
observed for cis-isomer 17 with one larger and two smaller coupling
constants (3J= 11.5 and 2×5.8 Hz) as a result of one axial-axial
coupling and two axial-equatorial protons. The alkyne functionality
was introduced using combined Sonogashira/Hiyama reaction condi-
tions with TMS-protected triethylorthopropiolate 18, which was syn-
thesized in a Grignard reaction from TMS-acetylene in high yield, to
obtain ethyl ester 19. The various amides were obtained by coupling
the corresponding amines to ester 19 using AlMe3 in DCM.
2.3. PDE-activity assay
The PDE-activity on TbrPDEB1 and hPDE4 of the synthesized al-
kynamides was measured to assess their potency and selectivity as
TbrPDEB1 inhibitors. Aliphatic alkynamides 20–27 showed comparable
submicromolar potencies against TbrPDEB1 in a pKi range of 6.0 to 6.5
Fig. 3. Virtual screening results. A) Number of hits of the docking in different TbrPDEB1 crystal structures indicated by PDB-code. B) Structures of the 6 amines found
in all three databases.
Scheme 1. Reagents and conditions: a) maleic anhydride, AlCl3, DCM, rt, overnight, 66%; b) 13% butadiene in THF, 140 °C (MW), 30min, 97%; c) N2H4·H2O, EtOH,
reflux, 4 h, 86%; d) 1) NaH, DMF, rt, 30min, 2) isopropylbromide, DMF, rt, 4 h, 81%; e) 1) iPrMgBr, Et2O, 10 °C, 30min; 2) tetraethoxymethane, Et2O, rt, 1 h, 93%; f)
PdCl2(dppf), CuI, CsF, Et3N, DMF, 120 °C (MW), 4 h, 70%; g) corresponding amine, K2CO3, AlMe3, (Et3N for HCl-salts), DCM, rt, overnight, 9–84%
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(Table 1). Most alkynamides showed similar or lower potency for
hPDE4 compared to TbrPDEB1, with the best selectivity index (SI,
TbrPDEB1 pKi – hPDE4 pKi) observed for the tetrahydrofuranyl-sub-
stituted analogue 26 (SI= 0.5).
The alkynamides that contain aromatic rings in the tail group (11,
12 and 28–41, Table 2) showed in general higher potencies for
TbrPDEB1 (pKi range 6.1–7.0) when compared to the aliphatic alky-
namides. Interestingly, both compounds that were directly selected
from the virtual screening (11 and 12) showed the lowest potency on
TbrPDEB1 observed for the aromatic series of alkynamides. There was
no difference observed between a furan and thiophene ring (28 and
30), both having a nanomolar potency against TbrPDEB1 (pKi= 6.9).
Introducing a methyl group on the furan (29) or elongating the tail
group for the thiophene (31) slightly reduced the potency for
TbrPDEB1. Implementing a thiazole ring (32–34) in the tail group did
not improve the potency or selectivity of the alkynamides.
Methylpyrrole 35 was equally potent against TbrPDEB1 as 2-methyl-
furan 28 and 2-methylthiophene 30, but with a slightly better SI
(Table 2, SI= 0.7). Imidazole 36 with a more flexible tail displayed a
reduced activity and selectivity.
The highest potencies were observed for pyridinyl alkynamides 38
(NPD-1169, pKi= 7.0) and 39 (NPD-1334, pKi= 7.0), which were
slightly more potent than the benzyl analogue 37 (pKi= 6.8), while the
less flexible 3-methoxyphenyl analogue 40 displayed a pKi of 6.7
against TbrPDEB1. Fluorophenyl 41 showed a slightly reduced potency
and selectivity when compared with benzyl analogue 37.
When compared to the previously synthesized primary alkynamide
7 with a SI of −0.3 (Fig. 4), most compounds (except 11) show a
slightly improved selectivity index for TbrPDEB1 over hPDE4 and
several compounds display a comparable selectivity to 5 (SI= 1.0). The
SI observed for 39 was 0.8 log unit, making this 4-pyridinyl alkynamide
approximately 6-times more potent against TbrPDEB1 than hPDE4.
2.4. Co-crystal structures in TbrPDEB1 and hPDE4
We successfully obtained co-crystal structures of 37, 40 and 41
(PDB: 6GXQ, 6RFN and 6RFW, respectively, Fig. 5) and the previously
reported NPD-053 (42) and NPD-055 (43) (PDB: 6RB6 and 6RGK, re-
spectively) in the catalytic domain of TbrPDEB1 and co-crystal struc-
tures of 37 and 42 bound in the catalytic domain of hPDE4 (PDB:
6HWO and 6RCW respectively). While our design indicated that dec-
oration of the alkynamide nitrogen of 7 is possible in TbrPDEB1 be-
cause of the presence of the parasite-specific P-pocket, the crystal
structures of 37 show that the amide substituent does not occupy the P-
pocket (Fig. 5A).
While a bidentate interaction with the key Gln874 of TbrPDEB1 is
maintained, the amide substituent folds back in a hydrophobic collapse. A
highly similar binding pose is observed in the co-crystal structure of 37 in
hPDE4 (Fig. 5B). The comparison of the co-crystal structures of 42 in
hPDE4 and TbrPDEB1 gave a similar result (See Supporting Info). While
the ligands do not seem to exploit the parasite-specific P-pocket, the crystal
structures do not give an explanation for the improved activity profile for
TbrPDEB1 over hPDE4. The tail groups seem to fold back towards Phe877
of the hydrophobic clamp, but no substantial additional interactions are
observed. In addition, an overlay of the binding poses of 37, 40, 41, 42 and
43 in the catalytic domain of TbrPDEB1 (Fig. 5C) shows that they occupy
the same space in the binding site (images of individual crystal structures
can be found in the Supporting Info).
2.5. Surface plasmon resonance biosensor analysis
To increase our understanding of ligand-PDE binding and the mo-
lecular features that have an influence on the resulting activity profiles,
we performed interaction analyses using a surface plasmon resonance
(SPR) biosensor assay (Fig. 6). Biotinylated proteins were captured by
neutravidin, immobilized on CM5 chip surface. Interaction assays were
performed by injecting suitable concentration series for each com-
pound. Compounds 20 and 37 were injected for respectively 60 and
320 s to reach steady-state equilibrium and their dissociation was
monitored (300 s for 20 and 900 s for 37) to determine the pKD values.
The affinity of the unsubstituted alkynamide 20 at hPDE4D
(pKD=6.6 ± 0.1) was ∼0.5 log unit higher compared to the affinity
obtained for its binding to TbrPDEB1 (pKD= 6.1 ± 0.1). Going from
20 to the benzyl substituted analog 37, the affinity for TbrPDEB1
(pKD=7.1 ± 0.1) improved 10-fold, while at hPDE4D
(pKD=7.1 ± 0.1) the affinity of 37 was only 0.5 log-unit higher.
These findings indicate that the benzyl substitution of the alkynamide
has a pronounced effect on TbrPDEB1 binding, as 37 is equipotent at
TbrPDEB1 and hPDE4. Interestingly, while the obtained crystal struc-
tures do not easily explain the improved biochemical activity profile of
Table 1
Structure-activity relationship of alkynamides with aliphatic tail groups for TbrPDEB1 and hPDE4.
pKi (mean ± S.E.M.)a pKi (mean ± S.E.M.)a
# NPD R TbrPDEB1 hPDE4 # NPD R TbrPDEB1 hPDE4
20 1170 6.3 ± 0.05 6.5 ± 0.1 24 1167 6.0 ± 0.1 6.1 ± 0.1
21 1024 6.5 ± 0.04 6.3 ± 0.1 25 1041 6.2 ± 0.1 6.4 ± 0.1
22 1038 6.4 ± 0.1 6.5 ± 0.1 26 1043 6.4 ± 0.1 5.9 ± 0.2
23 1042 6.5 ± 0.1 6.1 ± 0.1 27 1336 6.0 ± 0.1 6.1 ± 0.1
a Mean and S.E.M. values of at least 3 independent experiments.
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the new TbrPDEB1 inhibitors, the SPR biosensor analysis indicates
noteable differences in binding kinetics, as a much slower off-rates for
TbrPDEB1 and hPDE4 can be observed when comparing the dissocia-
tion kinetics of 20 and 37. The results indicate that binding kinetics
represent an opportunity to design new compounds with improved
activity profiles. We are currently developing in silico methods (in-
cluding but not limited to molecular dynamics studies) to translate
these kinetic binding data to molecular understanding.
2.6. Phenotypical data
All alkynamides were tested in vitro for their trypanocidal activity
against T. brucei trypomastigotes (Table 3). The best results were ob-
tained for 37 and 39, which both displayed submicromolar activities
and were not cytotoxic to MRC-5 cells. Aliphatic alkynamides (20–27)
showed a lower activity when compared to alkynamides with aromatic
tail groups (11, 12 and 28–41), as observed in the biochemical assay.
As displayed in Fig. 7, the alkynamides showed a good correlation
(R2= 0.7) between TbrPDEB1 and T. brucei activity. No correlation was
observed between important physicochemical properties (cLogP, cLogS
and TPSA) and their anti-T. brucei activity (graphic representation in
Supporting Info). Most alkynamides showed low or no cytotoxicity on
MRC-5 cells, except imidazole 36 that displayed a substantially higher
cytotoxicity when compared with other alkynamides. When compared
to alkynamide 7 (CC50= 5.0) most decorated alkynamides show an
improved cytotoxicity profile.
2.7. Intracellular real-time cAMP assay
To confirm on-target activity of 37 and 39 in live parasites, pro-
cyclic form trypanosomes expressing a FRET-based cAMP sensor were
incubated with 1 and 10 µM inhibitor 37 and 39 (Fig. 8). Both in-
hibitors induce a rapid and sustained increase in intracellular cAMP in
Table 2
Structure-activity relationship of alkynamides with aromatic tail groups.
pKi ± S.E.M.a pKi ± S.E.M.a
# NPD R TbrPDEB1 hPDE4 # NPD R TbrPDEB1 hPDE4
11 3154 5.6 ± 0.1b 6.3 ± 0.1 34 3153 6.7 ± 0.01 6.6 ± 0.3
12 3155 6.1 ± 0.02 5.9 ± 0.2 35 1321 6.9 ± 0.1 6.2 ± 0.1
28 1016 6.9 ± 0.04 6.4 ± 0.1 36 1323 6.4 ± 0.03 6.2 ± 0.2
29 1174 6.7 ± 0.2 6.7 ± 0.1 37 1335 6.8 ± 0.1 6.1 ± 0.2
30 1322 6.9 ± 0.04 6.3 ± 0.1 38 1169 7.0 ± 0.1 6.3 ± 0.1
31 1320 6.4 ± 0.01 6.1 ± 0.1 39 1334 7.0 ± 0.1 6.2 ± 0.1
32 1171 6.5 ± 0.1 6.0 ± 0.1 40 1018 6.7 ± 0.1 6.0 ± 0.1
33 1319 6.6 ± 0.1 6.4 ± 0.2 41 1039 6.5 ± 0.1 6.1 ± 0.1
a Mean and S.E.M. values of at least 3 independent experiments.
Fig. 4. Biochemical activity against TbrPDEB1 and hPDE4 of all alkynamides
and reference compounds NPD-008 (5) and NPD-048 (7). The selectivity index
(pKi TbrPDEB1 – pKi hPDE4) is indicated by colour.
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Fig. 5. Crystal structures of alkynamides in the catalytic domain of TbrPDEB1 (blue) and hPDE4 (red). Key residues, active site water molecules and metals are shown
for clarity. A) Overlay of 7 (grey) and 37 (blue) in TbrPDEB1 with the P-pocket shown in grey. B) Binding pose of 37 in the catalytic domain of TbrPDEB1 (blue) and
hPDE4 (red). C) Overlay of all obtained crystal structures of alkynamides 37 (blue), 40 (cyan) and 41 (orange), 42 (magenta) and 43 (green) bound to the catalytic
domain of TbrPDEB1. D) Structures of the co-crystallized compounds and their colour of visualisation.
Fig. 6. Sensorgrams of compound 20 binding to hPDE4D (A) and TbrPDEB1 (B), and compound 37 binding to hPDE4D (C) and TbrPDEB1 (D). Inset shows steady-
state affinity analyses of SPR biosensor interaction data; blank injections are also shown. Measurements using two independent biosensor chips and three different
stock solutions indicate good reproducibility (see supplementary information).
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the reporter cell line versus the negative control (DMSO), as indicated
by an increase in 488/535 nm emission ratio. Both inhibitors were
compared with a known non-selective TbrPDEB1 inhibitor (NPD-001),
which was previously reported to increase intracellular cAMP levels in
bloodstream and procyclic form trypanosomes.18,33 Both inhibitors 37
and 39 show a higher response at 1 µM when compared with reference
inhibitor NPD-001 and an equal response at 10 µM.
To determine the activity of inhibitor 37 and 39 on bloodstream
form trypanosomes, parasites were incubated with inhibitor 37 and 39
for 24–48 h prior to fixation and cellular analysis by fluorescence mi-
croscopy. After incubation with inhibitor 37 and 39, bloodstream form
trypanosomes exhibit a lethal block in cytokinesis, indicated by multi-
nucleated and multi-flagellated parasites (Fig. 9). The trypanocidal ef-
fects of 37 and 39 are in line with previous observations after genetic
and pharmacological modulation of TbrPDEB1 and TbrPDEB2 expres-
sion or function in bloodstream form trypanosomes.16,19
3. Conclusion
The structure-based design of alkynamide phthalazinones as
TbrPDEB1 inhibitors delivered several compounds with a sub-
micromolar activity against TbrPDEB1 and a modest selectivity over its
human homologue hPDE4. Unexpectedly, alkynamide 37 did not show
the predicted P-pocket occupation by the tail group in the co-crystal
structure with TbrPDEB1 and a very similar binding mode was observed
in the co-crystal structure with hPDE4. This observation indicates that
targeting of the P-pocket of TbrPDEB1 is difficult to achieve with al-
kynamide tetrahydrophthalazinones. Moreover, the observed (mod-
erate) selectivity of the benzyl and the two pyridinyl-substituted alky-
namides 37, 38 and 39 suggests that other, as of yet unidentified
interactions of PDE inhibitors with TbrPDEB1 and hPDE4 can also re-
sult in (moderate) parasite selectivity. The alkynamides show a good
correlation between their biochemical activity against TbrPDEB1 and
their in vitro activity against T. brucei parasites. Benzyl alkynamide 37
(NPD-1335) is 5-fold more potent against TbrPDEB1 (pKi= 6.9) than
hPDE4 (pKi= 6.2) and displays a greatly improved cytotoxicity profile
(pIC50 T. brucei=6.2 vs pCC50 MRC-5 < 4.2) when compared to the
unsubstituted alkynamide 7 (pIC50 T. brucei=6.0 vs pCC50 MRC-
5 < 5.0). Furthermore, incubation of procyclic forms with 37 and 39
results in elevation of the intracellular cAMP levels in the cells. In
bloodstream forms, incubation with 37 and 39 leads to a block in cy-
tokinesis, which is associated with formation of multiple flagella and
nuclei, both supporting a PDE-mediated mode of action.
4. Experimental
4.1. Docking
The dockings were performed similar to the combined screening
protocol as previously published for GPCRs.30 In short, the dockings
were performed using PLANTS28 (version 1.2) and the resulting docking
poses were post-processed with IFP29 (version 2.2). Every molecule was
docked 5 times generating 10 docking poses during each iteration
(speed setting 2, RMSD 1.0) into each of the three crystal structures
(chain B for 5G2B and 5L8Y and chain A for 6FTM) based on the pocket
definition as defined for PDEStrIAn.34 All docking poses were scored
using the ChemPLP scoring function and only poses with a score ≤−90
were further investigated. The positioning of the core scaffold was
evaluated by performing an IFP similarity comparison to the co-crys-
tallized ligands limited to solely the residues in the direct vicinity of the
core scaffold. Poses with an IFP score lower than 0.5 or where the li-
gand did not interact with the conserved glutamine (Q.50) or the hy-
drophobic clamp (HC.32, HC.52) were removed. A final interaction
filter was applied to select only those binding modes in which the Q2
pocket was targeted by having at least one IFP contact with Q2.45 or
Q2.46. From the initial combinatorial library of 16,153 alkynamides
2291 compounds remained for further processing.
4.2. Protein production
Cloning, expression and purification of recombinant TbrPDEB1 and
hPDE4D catalytic domains were performed as previously described.25
4.3. Crystallization, data collection and structure determination
Apo crystals of TbrPDEB1 and hPDE4D were grown in 24 well XRL
plates (Molecular Dimensions, Newmarket, Suffolk, UK) by vapor dif-
fusion hanging drop technique. Typically, protein and crystallization
solution were mixed in 1:1 ratio and drops were setup against 500 μL
reservoir solution. Crystals of TbrPDEB1 were obtained in a condition
containing 20% PEG 3350, 400mM sodium formate, 300mM guani-
dine and 100mM MES pH 6.5 at 4 °C and soaked with different in-
hibitors to obtain protein-inhibitor complexes. hPDE4D crystals
Table 3
Trypanocidal activity of all alkynamides against T. brucei parasites and their
cytotoxicity against human MRC-5 cells.
# cLogP cLogS TPSA T. brucei (pIC50) MRC-5 (pCC50)
20 2.4 −4.3 85 5.2 ± 0.1 4.5 ± 0.1
21 3.9 −5.4 71 5.1 ± 0.1 < 4.2
22 3.4 −5.2 71 5.1 ± 0.1 < 4.2
23 3.8 −5.7 71 5.2 ± 0.1 < 4.2
24 2.4 −4.5 95 4.6 ± 0.1 4.5 ± 0.1
25 2.4 −4.9 86 5.1 ± 0.1 5.1 ± 0.1
26 3.0 −4.9 80 5.1 ± 0.1 4.5 ± 0.1
27 2.6 −4.7 71 5.0 ± 0.1 4.5 ± 0.1
11 3.0 −4.3 102 <4.2 5.0 ± 0.2
12 3.7 −5.2 113 5.7 ± 0.1 5.1 ± 0.1
28 3.4 −5.3 84 5.6 ± 0.1 < 4.2
29 3.6 −5.5 84 5.5 ± 0.3 < 4.2
30 4.2 −5.9 71 6.0 ± 0.4 4.2 ± 0.1
31 4.5 −5.8 71 5.6 ± 0.1 < 4.2
32 3.2 −4.7 84 5.7 ± 0.1 4.9 ± 0.1
33 3.3 −4.6 84 5.3 ± 0.2 5.0 ± 0.1
34 3.4 −4.8 84 5.7 ± 0.1 5.1 ± 0.1
35 2.7 −4.0 89 5.8 ± 0.3 4.7 ± 0.1
36 2.6 −4.5 89 5.1 ± 0.1 6.6 ± 0.1
37 4.3 −5.9 71 6.2 ± 0.1 < 4.2
38 3.1 −4.7 84 5.9 ± 0.1 5.4 ± 0.2
39 3.1 −4.7 84 6.0 ± 0.4 4.5 ± 0.4
40 4.5 −6.0 80 5.8 ± 0.1 < 4.2
41 4.7 −6.1 71 5.7 ± 0.1 < 4.2
Fig. 7. Correlation between TbrPDEB1 activity and cellular activity against T.
brucei parasites of all alkynamides and reference compounds NPD-048 and
NPD-008.
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obtained in a condition containing 24% PEG 3350, 30% ethylene glycol
and 100mM HEPES pH 7.5 at 19 °C were complexed with different
inhibitors in a similar way. The soaked crystals were then cryo
protected, mounted on CryoLoop (Hampton Research, Aliso Viejo, CA,
USA) or LithoLoops (Molecular Dimensions) and vitrified in liquid ni-
trogen for data collection. All X-ray diffraction data sets were collected
Fig. 8. Intracellular cAMP levels in procyclic form trypanosomes upon incubation with inhibitor A) 37 and B) 39 at two concentrations (1 µM and 10 µM) compared
to NPD-001 and control cells.
Fig. 9. Fluorescence microscopy of control trypanosomes and trypanosomes incubated with 37 or 39 after 24–48 h visualized with different stains. First column
shows cells under normal microscope conditions. Second and third column show the cells with DAPI and PFR stains respectively to visualise cell nuclei (DAPI) and the
flagellum (PFR). Overlay of the different imaging techniques is shown in the fourth column.
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at Diamond Light Source (DLS; Didcot, Oxfordshire, UK) at beam lines
I03 using a Pilatus 6M detector (Dectris, Baden, Switzerland) or at I04-
1 using a Pilatus 6M−F detector (Dectris) at 100 K temperature.
Datasets were processed with xia235 or autoPROC36 pipelines available
at DLS, which incorporates XDS37 and AIMLESS,38 or were integrated
using iMOSFLM39 and reduced using POINTLESS, AIMLESS and TRU-
NCATE, all of which are part of CCP4 suite.40 Structures of inhibitor
complexes with TbrPDEB1 and hPDE4D were determined by molecular
replacement in CCP4 suite program PHASER41 by using the respective
apo models (TbrPDEB1, PDB id: 4I15; hPDE4D, PDB id: 3SL3) as search
templates. Stereochemical restrains for the inhibitors were generated by
ACEDRG available within the CCP4 package and ligand fitting and
model adjustment were carried out in COOT42 followed by their re-
finement in REFMAC.43 Data processing and refinement statistics are
given in Tables 4 and 5. Structural figures were prepared with
PYMOL44. Coordinates of the structures have been deposited to the
RCSB Protein Data Bank with following accession codes: 6GXQ
(TbrPDEB1-NPD-1335), 6RFN (TbrPDEB1-NPD-1018), 6RFW
(TbrPDEB1-NPD-1039), 6RB6 (TbrPDEB1-NPD-053), 6RGK
(TbrPDEB1-NPD-055), 6HWO (hPDE4D-NPD-1335) and 6RCW
(hPDE4D-NPD-053).
4.4. Phosphodiesterase activity assays
Phosphodiesterase activity assays are performed using the
PDELight™ HTS cAMP phosphodiesterase Kit (Lonza, Walkersville,
USA): The assay is performed at 25 °C in non-binding, low volume 384
wells plates (Corning, Kennebunk, ME, USA). PDE activity measure-
ments (TbrPDEB1_CD; Km 3.45 µM, hPDE4B_CD; Km 13.89 µM) are
made in ‘stimulation buffer’ (50mM Hepes, 100mM NaCl, 10mM
MgCl, 0.5 mM EDTA, 0.05mg/mL BSA, pH 7.5). Single concentration
measurements are made at 10 µM inhibitor concentration (triplo
Table 4
Data collection and refinement statistics for TbrPDEB1 crystals bound to various inhibitors.
Data collection NPD-1335 NPD-1018 NPD-1039 NPD-053 NPD-055
Synchrotron and Beamline Diamond I04-1 Diamond I03 Diamond I03 Diamond I04-1 Diamond I03
Space group C2 C2 C2 C2 C2
Molecule/a.s.u 2 2 2 2 2
Celll dimensions a, b, c (Å) 114.73, 114.54, 68.20 114.71, 116.08, 68.67 113.72, 116.55, 68.53 147.51, 115.07, 63.78 114.78, 116.48, 68.61











Rmerge 0.09 (0.70) 0.07 (0.55) 0.04 (0.57) 0.09 (0.62) 0.06 (1.17)
I/σI 6.0 (1.3) 10.7 (2.3) 15.3 (2.1) 7.2 (2.0) 11.5 (1.1)
CC(1/2) 0.99 (0.59) 0.99 (0.86) 0.99 (0.88) 0.99 (0.47) 0.99 (0.59)
Completeness (%) 99.8 (99.9) 98.3 (96.5) 96.9 (97.7) 99.7 (99.9) 99.7 (99.7)
Redundancy 3.3 (3.3) 3.4 (3.3) 3.3 (3.3) 3.1 (3.3) 3.4 (3.4)
Refinement
Resolution (Å) 1.96 2.29 2.18 1.90 2.03
No. reflections 55,439 36,118 40,644 74,823 52,428
Rwork/Rfree 0.20/0.24 0.16/0.22 0.17/0.23 0.16/0.19 0.18/0.23
No. atoms
Protein 5260 5260 5248 5278 5260
Water 433 339 270 418 336
B-factors (Å2)














Bond lengths (Å) 0.008 0.010 0.009 0.010 0.007
Bond angles (°) 1.247 1.683 1.558 1.713 1.465
PDB accession code 6GXQ 6RFN 6RFW 6RB6 6RGK
PDB ligand code FFZ K3W K1Q JX2 K3N
Data collected from a single crystal.
*Values in parentheses are for highest-resolution shell
Table 5
Data collection and refinement statistics for hPDE4D crystals bound to NPD-
1335 and NPD-053.
Data collection NPD-1335 NPD-053
Synchrotron and Beamline Diamond I04-1 Diamond I03
Space group P212121 P212121
Molecule/a.s.u 4 4
Cell dimensions a, b, c (Å) 98.54, 110.89, 160.39 99.89, 110.50, 160.69





Rmerge 0.06 (0.70) 0.06 (0.79)
I/σI 14.1 (2.0) 16.2 (2.0)
CC(1/2) 0.99 (0.58) 0.99 (0.75)
Completeness (%) 100 (1 0 0) 99.9 (94.8)
Redundancy 6.5 (6.6) 6.6 (6.8)
Refinement
Resolution (Å) 1.99 2.08














Bond lengths (Å) 0.019 0.01
Bond angles (°) 1.935 1.653
PDB accession code 6HWO 6RCW
PDB ligand code FFZ JX2
*Values in parentheses are for highest-resolution shell.
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measurements/assay, n= 2). Dose response curves are made in the
range 100 µM−10 pM (triplo measurements/assay, n=3). Compounds
are diluted in DMSO (final concentration 1%). Inhibitor dilutions
(2.5 µL) are transferred to the 384 wells plate, 2.5 µL PDE in stimulation
buffer is added and mixed, 5 µL cAMP (at 2×Km up to 20 µM) is added
and the assay is incubated for 20min at 300 rpm. The reaction is ter-
minated by then addition of 5 µL Lonza Stop Buffer supplemented with
10 µM NPD-001. Then 5 µL of Lonza Detection reagent (diluted to 80%
with reaction buffer) is added and the reaction incubated for 10min at
300 rpm. Luminescence is read with a Victor3 luminometer using a
0.1 s/well program.
RLUs were measured in comparison to the DMSO-only control, NPD-
001 always was taken along as positive control as a PDE inhibitor. The
Ki values of the inhibitors analyzed are represented as the mean of at
least three independent experiments with the associated standard error
of the mean (SEM) as indicated.
4.5. Phenotypic cellular assays
For the cellular assays, the following reference drugs were used as
positive controls: suramin (Sigma-Aldrich, Germany) for T. brucei
(pIC50= 7.4 ± 0.2, n=5), and tamoxifen (Sigma-Aldrich, Germany)
for MRC-5 cells (pCC50= 5.0 ± 0.1, n=5). All compounds were
tested at five concentrations (64, 16, 4, 1 and 0.25 µM) to establish
determination of the IC50 and CC50. Data are represented as the mean of
duplicate experiments ± S.E.M. The final concentration of DMSO did
not exceed 0.5% in the assays.
In vitro antitrypanosomal assay. T. brucei Squib-427 strain (suramin-
sensitive) was cultured at 37 °C and 5% CO2 in HMI-9 medium, sup-
plemented with 10% heat-inactivated fetal calf serum (FCSi). About
1.5×104 trypomastigotes were added to each well and parasite growth
was assessed after 72 h at 37 °C by adding resazurin. Viability was as-
sessed fluorimetrically 24 h after the addition of resazurin. Fluorescence
was measured (excitation 550 nm, emission 590 nm) and the results
were expressed as percentage reduction in viability compared to con-
trol.
In vitroMRC-5 cytotoxicity assay. MRC-5 SV2 cells, originally from a
human diploid lung cell line, were cultivated in MEM, supplemented
with L-glutamine (20mM), 16.5mM sodium hydrogen carbonate and
5% FCSi. For the assay, 104 MRC-5 cells/well were seeded onto the 96-
well test plates containing the pre-diluted sample and incubated at
37 °C and 5% CO2 for 72 h. Cell viability was assessed fluorimetrically
4 h after the of addition of resazurin. Fluorescence was measured (ex-
citation 550 nm, emission 590 nm) and the results were expressed as
percentage reduction in cell viability compared to control.
4.6. Intracellular cAMP and fluorescence microscopy
4.6.1. Cell lines
Procyclic 2913 T. b. brucei45 were cultivated in SDM-79 supple-
mented with 5% FCSi46 Bloodstream-form T. b. brucei 221 single marker
cell line45 were cultivated in HMI-9 medium supplemented with 10%
FCSi46 The cAMP FRET reporter cell line was developed by transfecting
2913 procyclic form T. b. brucei with linearized pLEW-100 containing
epac1camps. Selection for transfected cells and cloning by limited di-
lution was done as published previously.46 Expression of epac1-camps
was validated using fluorescence microscopy.
4.6.2. Plasmids
For tetracycline inducible expression of the cAMP FRET sensor, the
Epac1camps sensor47 was cloned into pLEW-10045 as described.33
4.6.3. Chemicals
NPD-001, 37, 39 were dissolved in DMSO to 1 and 10mM and
stored at −80 °C.
4.6.4. FRET assay
cAMP FRET assays were performed in triplicates for each time point
and 3 independent experiments, as described previously33: As controls,
NPD-001 (positive control,18 and DMSO (solvent for 37, 39, NPD-001))
were included. The following modifications to the published method33
were made: the cAMP reporter cell line was cultivated in SDM-79
containing 5% FCSi. After induction of Epac1-camps expression with
tetracycline46 for 24 h-48 h, the cells were washed once and re-
suspended in PBS containing 5% FCSi to 1.5× 108 cells/mL. 150 µL of
cells was added to each well of a 96-well black microtiter plate. 50 µL of
NPD-001, 37, 39 and DMSO diluted in PBS containing 5% FCSi was
added to the wells (final concentration of compounds: 10 µM).
4.6.5. Microscopy
Bloodstream-form T. b. brucei 221 single marker cell line were cul-
tivated for 24 h in the presence of 1 µM NPD-001, 37, 39 or DMSO as
control. Methodology used for cell fixation and staining has been de-
scribed previously,48 with the following modifications: blocking and
antibody staining was done in PBS containing 5% bovine serum al-
bumin (BSA). Antibodies used were rat anti-PFR 1:50049 and anti-rat
Alexa594 1:500 (Invitrogen). NucBlue Fixed Cell Stain (Invitrogen) was
added to Vectashield mounting medium (for DNA stain). Images were
acquired using a Leica confocal microscope and standard procedures.
Images were processed using ImageJ.
4.7. Surface plasmon resonance
All experiments were performed with a Biacore T200 surface
plasmon resonance biosensor instrument (GE healthcare). Proteins
were immobilized on CM5 series S sensor chips. Consumables were
obtained from GE Healthcare. All solutions were freshly prepared, de-
gassed, and filtered. The neutravidin immobilization was run on HBS-N
at a flowspeed of 10 µL/min at 25 °C. The matrix of the sensor chip was
activated by injecting on all flow channels a mixture of 0.1MN-hy-
droxysuccinimide (NHS) and 0.4M 1-ethyl-3-(3-(dimethylamino)
propyl) carbodiimidehydrochloride (EDC) at a flow rate of 10 µM for
420 s. Subsequently, neutravidin (0.30mg/mL) in a 10mM NaAc so-
lution (pH 5.0) was injected for 120 s. Unreacted activated groups of
the dextran matrix were deactivated by injection of ethanolamine.HCl
(1M) for 420 s.
The catalytic domains of hPDE4D and TbrPDEB1 were produced
and purified as previously described.25 the proteins were buffer ex-
changed using a Amicon Ultra 0.5 mL centrifugal filter (Merk) to HBS-
N, 5% glycerol (v/v), 4 µM MgCl2·6H2O, 100 nM ZnCl2, 2 mM 2-mer-
captoethanol and diluted to 1mg/mL. EZ-Link Sulfo-NHS-Biotin
(Thermo Fisher Scientific) was diluted to 1.5 mM in the same buffer,
mixed with the protein in a 1:1M ratio, and incubated at 4 °C overnight.
Biotinylated proteins were buffer exchanged to 0.5M Tris-HCl (pH 8.0),
150mM NaCl, 4mM MgCl2·6H2O, 100 nM ZnCl2, 5% glycerol (v/v),
2 mM 2-mercaptoethanol, and desalted using 0.5 mL Zeba Spin de-
salting columns (Thermo Scientific). Proteins were diluted to 0.5mg/
mL and injected on the flow channels until 3000 RU in the same buffer
at 15 °C. Biocytin (0.05mg/mL) was injected for 120 s on all flow
channels at 15 °C.
All compounds were dissolved in DMSO (stock solutions of 10mM)
and diluted in 0.5M Tris-HCl (pH 8.0), 150mM NaCl, 4 mM
MgCl2·6H2O, 100 nM ZnCl2, 5% glycerol (v/v), 2 mM 2-
Mercaptoethanol, 0.005% Tween-20 (v/v), 2% DMSO (v/v). Suitable
concentration series and injection times were determined for each
compound separately. In multicycle experiments, a 7-point concentra-
tion range of each compound was measured. On a first CM5 chip, a first
stock solution was used to obtain a dose response curve in duplicate. On
a second CM5 chip, two other independent stock solutions were used to
measure dose response curves in duplicate. Compound 20 was injected
for 60 s and its dissociation was monitored for 300 s. Compound 37 was
injected for 420 s and its dissociation was monitored for 900 s. All
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titrations were run at 25 °C at a flow speed of 50 µL/min. Data analyses
were performed with Scrubber2. Signals were subtracted from re-
ference surface and blanc injections. DMSO correction was performed.
The affinity was determined by fitting a Langmuir binding equation to
steady state binding signals at different concentrations. All SPR ex-
periments are shown in the Supplementary data with individually




All reagents and solvents were obtained from commercial suppliers
and were used as received. All reactions were magnetically stirred and
carried out under an inert atmosphere. Reaction progress was mon-
itored using thin-layer chromatography (TLC) and LC-MS analysis. LC-
MS analysis was performed on a Shimadzu LC-20AD liquid chromato-
graph pump system, equipped with an Xbridge (C18) 5 µm column
(50mm, 4.6mm), connected to a Shimadzu SPD-M20A diode array
detector, and MS detection using a Shimadzu LC-MS-2010EV mass
spectrometer. The LC-MS conditions were as follows: solvent A (water
with 0.1% formic acid) and solvent B (acetonitrile with 0.1% formic
acid), flow rate of 1.0mL/min, start 5% B, linear gradient to 90% B in
4.5 min, then 1.5 min at 90% B, then linear gradient to 5% B in 0.5 min,
then 1.5min at 5% B; total run time of 8min. Silica gel column chro-
matography was carried out with automatic purification systems using
the indicated eluent. Reversed phase column purification was per-
formed on Grace Davison iES system with C18 cardridges (60 Å, 40 μm)
using the indicated eluent. Nuclear magnetic resonance (NMR) spectra
were recorded as indicated on a Bruker Avance 500 (500MHz for 1H
and 125.8MHz for 13C) instrument equipped with a Bruker
CryoPlatform, or on a Bruker Avance III HD (600MHz for 1H) instru-
ment equipped with a Bruker CryoPlatform. Chemical shifts (δ in ppm)
and coupling constants (J in Hz) are reported with residual solvent as
internal standard (δ 1H NMR: CDCl3 7.26; DMSO-d6 2.50; δ 13C NMR:
CDCl3 77.16; DMSO-d6 39.52). Abbreviations used for 1H NMR de-
scriptions are as follows: s= singlet, d= doublet, t= triplet,
q= quintet, hept= heptet dd= doublet of doublets, dt= doublet of
triplets, tt = triplet of triplets, m=multiplet, app d= apparent
doublet, br= broad signal. Exact mass measurement (HRMS) was
performed on a Bruker micrOTOF-Q instrument with electrospray io-
nization (ESI) in positive ion mode and a capillary potential of 4,500 V.
Systematic names for molecules were generated with ChemBioDraw
Ultra 14.0.0.117 (PerkinElmer, Inc.). The reported yields refer to iso-
lated pure products and yields were not optimized. The purity, reported
as the LC peak area % at 254 nm, of all final compounds was ≥95%
based on LC-MS. All compounds are isolated as a racemic mixture of cis-
enantiomers.
4.8.2. Synthetic procedures
4.8.2.1. (E)-4-(3-Bromo-4-methoxyphenyl)-4-oxobut-2-enoic acid (14). To
an ice-cooled mixture of 1-bromo-2-methoxybenzene (65mL, 0.52mol)
and furan-2,5-dione (77 g, 0.78mol) in DCM (465mL) was added AlCl3
(84 g, 0.63mol). The reaction mixture was stirred at rt overnight. The
orange suspension was quenched in 3M aq. HCl (1.5 L) and extracted using
EtOAc (4×1 L). The combined organic layers were dried over Na2SO4,
filtered and concentrated to obtain a dark yellow solid. Trituration with
Et2O provided the product as a light yellow solid (97.5 g, 66%).
LC-MS (ESI): tR= 4.09min, area:> 98%, m/z: 285/287 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.89 (d, J=2.2 Hz, 1H), 7.69 (dd,
J=8.7, 2.2 Hz, 1H), 7.53 (d, J=15.4 Hz, 1H), 6.74 (d, J=8.7 Hz,
1H), 6.51 (d, J=15.4 Hz, 1H), 3.69 (s, 3H).
13C NMR (126MHz, DMSO-d6): δ 187.2, 167.1, 166.7, 160.2, 136.3,
133.8, 133.0, 131.3, 130.6, 112.9, 111.8, 57.3.
HRMS (ESI): m/z: [M+H]+ calcd. for C11H10BrO4 284.9757, found
284.9763.
4.8.2.2. Trans-6-(3-Bromo-4-methoxybenzoyl)cyclohex-3-ene-1-carboxy-
lic acid (15). A mixture of 14 (70.0 g, 221mmol) and buta-1,3-diene in
THF (∼13% w/w, 150mL, 300mmol) was divided over 8 microwave
vials. Each vial was stirred under microwave irradiation at 140 °C for
30min (the internal pressure reached∼10 bar). The reaction mixtures
were pooled and concentrated in vacuo to obtain the crude product.
Trituration with toluene provided the product as a white solid (72.4 g,
97%).
LC-MS (ESI): tR= 4.53min, area:> 98%, m/z: 339/341 [M+H]+
1H NMR (500MHz, DMSO-d6): δ 12.30 (s, 1H), 8.16 (s, 1H), 8.07 (d,
J=8.7 Hz, 1H), 7.23 (d, J=8.5 Hz, 1H), 5.79–5.66 (m, 2H), 3.95 (s,
3H), 3.83–3.72 (m, 1H), 2.92–2.75 (m, 1H), 2.54–2.10 (m, 3H),
1.93–1.79 (m, 1H).
13C NMR (126MHz, DMSO-6): δ 200.8, 176.4, 159.61 133.4, 130.6,
130.3, 125.8, 125.7, 112.8, 111.6, 57.2, 42.2, 41.6, 29.4, 28.4.
HRMS (ESI): m/z: [M+H]+ calcd. for C15H16BrO4 339.0226, found
339.0213
4.8.2.3. Trans-4-(3-Bromo-4-methoxyphenyl)-4a,5,8,8a-tetrahydrophth-
alazin-1(2H)-one (16). A solution of 15 (70 g, 0.21mol) and hydrazine
monohydrate (32mL, 0.62mol) in EtOH (400mL) was stirred at reflux
for 4 h. The reaction mixture was cooled in the refridgerator and
filtered to obtain the pure product as a white solid (60 g, 86%). Note:
Partial conversion of stereochemistry during the condensation reaction
was observed only once (out of 5) during a small scale reaction
(< 3mmol).
LC-MS (ESI): tR= 4.29min, area:> 98%, m/z: 335/337 [M+H]+.
1H NMR (600MHz, DMF-d7) δ 10.98 (s, 1H), 7.74 (d, J=2.1 Hz,
1H), 7.52 (dd, J=8.5, 2.1 Hz, 1H), 7.22 (d, J=8.5 Hz, 1H), 5.82–5.64
(m, 2H), 3.98 (s, 3H), 3.14 (ddd, J=14.6, 11.4, 5.4 Hz, 1H), 2.57 (td,
J=14.2, 13.3, 5.4 Hz, 2H), 2.51–2.43 (m, 1H), 2.22–2.10 (m, 1H),
1.94–1.84 (m, 1H).
13C NMR (126MHz, DMSO-d6): δ 168.9, 155.9, 153.8, 132.3, 130.9,
128.7, 126.1, 125.9, 112.4, 110.5, 56.8, 36.2, 34.3, 30.3, 26.2.
HRMS (ESI): m/z: [M+H]+ calcd. for C15H16BrN2O2 335.0390,
found 335.0378.
4.8.2.4. Cis-4-(3-Bromo-4-methoxyphenyl)-2-isopropyl-4a,5,8,8a-tetra-
hydrophthalazin-1(2H)-one (17). To a solution of 16 (50.0 g, 0.15mol)
in DMF (500mL) was added NaH (15 g, 0.37mol) and the reaction
mixture was stirred at rt for 30min. 2-bromopropane (21mL, 22mmol)
was added to the reaction mixture and the reaction mixture was stirred
at rt for 4 h. The reaction mixture was quenched with aq. HCl (0.5M,
1.5 L) on ice. The suspension was filtered and the residue was dissolved
in MeOH/DCM. The solution was dried over Na2SO4, filtered and
concentrated in vacuo. The residue was triturated with Et2O to obtain
the product as white crystals (46 g, 81%).
LC-MS (ESI): tR= 5.30min, area:> 98%, m/z: 377/379 [M+H]+.
1H NMR (600MHz, CDCl3) δ 8.04 (s, 1H), 7.74 (d, J=8.6 Hz, 1H),
6.94 (d, J=8.6 Hz, 1H), 5.85–5.65 (m, 2H), 5.05 (hept, J=6.3 Hz,
1H), 3.95 (s, 3H), 3.28 (dt, J=11.5, 5.8 Hz, 1H), 3.07–2.96 (m, 1H),
2.74 (t, J=6.1 Hz, 1H), 2.26–2.12 (m, 2H), 2.08–1.96 (m, 1H), 1.33 (d,
J=6.6 Hz, 3H), 1.22 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.5, 156.8, 152.9, 130.4, 129.2,
127.3, 126.3, 124.4, 113.0, 111.6, 56.9, 46.2, 34.3, 30.3, 22.9, 22.4,
20.9, 20.6.
HRMS (ESI): m/z: [M+H]+ calcd. for C18H22BrN2O2 377.0859,
found 377.0871.
4.8.2.5. Trimethyl(3,3,3-triethoxyprop-1-yn-1-yl)silane
(18). Magnesium (1.38 g, 56.7mmol) was activated using a mortar and
pestle and was suspended in dry Et2O (25mL). 2-bromopropane
(5.33mL, 56.7 mmol) was slowly added to the stirring reaction
mixture while cooling with water (the reaction mixture starts to
reflux). The reaction mixture was stirred in a cold water bath for
30min prior to the addition of ethynyltrimethylsilane (6.68mL,
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47.3mmol). This reaction mixture was stirred for an additional 30min
to form a thick grey suspension, which was diluted with Et2O (25mL)
prior to slow addition of tetraethoxymethane (10.9mL, 52.0mmol).
After 1 h the reaction mixture turned into a dark brown/colourless
mixture (two phases). The reaction mixture was poured in saturated aq.
NH4Cl (500mL) and was extracted with Et2O (2×500mL). The
organic phase was concentrated and the product was isolated as a
light yellow liquid (10.5 g, 93%).
1H NMR (500MHz, DMSO-d6): δ 3.55 (q, J=7.1 Hz, 6H), 1.12 (t,
J=7.2 Hz, 9H), 0.18 (s, 9H).
13C NMR (126MHz, DMSO-d6): δ 107.8, 99.2, 88.0, 58.3, 14.7,
−0.5.
HRMS (ESI): m/z: [M+Na]+ calcd. for C12H24NaO3Si 267.1387,
found 267.1376.
4.8.2.6. Ethyl 3-(5-(cis-3-isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2-methoxyphenyl)propiolate (19). To a N2-purged solution of 17
(0.50 g, 1.3mmol) in DMF (2mL) and Et3N (2mL) was added
subsequently 18 (0.65 g, 2.7mmol), PdCl2(dppf) (49mg, 0.66mmol), CuI
(25mg, 0.13mmol) and CsF (0.30 g, 1.99mmol). The mixture was stirred
in the microwave at 120 °C for 4 h. The reaction mixture was poured in 1M
aq. HCl (250mL) and extracted with EtOAc (2×250mL). The organic
phase was washed with brine (250mL), dried over MgSO4, filtered and
concentrated to obtain the crude product as a brown solid. The crude
product was purified using flash column chromatography (0–50% EtOAc/
Hept). The product was obtained as a light yellow solid (0.37 g, 70%).
LC-MS (ESI): tR= 5.31min, area:> 98%, m/z: 395 [M+H]+.
1H NMR (500MHz, DMSO-d6): δ 8.10–7.99 (m, 2H), 7.25 (d,
J=8.9 Hz, 1H), 5.74–5.56 (m, 2H), 4.88 (hept, J=6.6 Hz, 1H), 4.25
(q, J=7.1 Hz, 2H), 3.93 (s, 3H), 3.51 (dt, J=11.5, 5.8 Hz, 1H), 2.80
(t, J=6.0 Hz, 1H), 2.78–2.69 (m, 1H), 2.23–2.06 (m, 2H), 1.86–1.72
(m, 1H), 1.33–1.20 (m, 6H), 1.15 (d, J=6.8 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.6, 162.5, 153.6, 153.0, 132.3,
131.1, 128.1, 126.3, 124.5, 112.6, 108.1, 84.9, 82.9, 62.5, 56.8, 46.2,
34.3, 30.2, 22.8, 22.4, 20.9, 20.6, 14.4.
HRMS (ESI): m/z: [M+H]+ calcd. for C23H27N2O4 395.1965, found
395.1952.
4.8.2.7. 3-(5-(cis-3-Isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-
1-yl)-2-methoxyphenyl)propiolamide (20). Ester 19 (0.50 g, 1.27mmol)
was dissolved in a solution of NH3 in MeOH (7M, 4mL, 28.0mmol) and
stirred at rt for 2 h. The reaction mixture was concentrated and the
crude product was purified using flash column chromatography
(gradient: 0–50% EtOAc/Hept). The product was obtained as a white
solid (390mg, 84%).
LC-MS (ESI): tR= 4.19min, area:> 98%, m/z: 366 [M+H]+.
1H NMR (500MHz, DMSO-d6): δ 8.14 (s, 1H), 8.01–7.91 (m, 2H),
7.69 (s, 1H), 7.20 (d, J=8.8 Hz, 1H), 5.75–5.57 (m, 2H), 4.88 (p,
J=6.6 Hz, 1H), 3.90 (s, 3H), 3.45 (dt, J=11.6, 5.7 Hz, 1H), 2.81 (t,
J=6.0 Hz, 1H), 2.78–2.68 (m, 1H), 2.25–1.99 (m, 2H), 1.80 (t,
J=14.8 Hz, 1H), 1.24 (d, J=6.4 Hz, 4H), 1.14 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.5, 161.7, 154.4, 153.1, 131.6,
129.9, 127.8, 126.3, 124.4, 112.3, 109.7, 88.5, 80.0, 56.6, 46.2, 34.2,
30.3, 22.9, 22.3, 20.9, 20.6.
HRMS (ESI): m/z: [M+H]+ calcd. for C21H24N3O3 366.1812, found
366.1797.
4.8.2.8. General procedure for alkynamide synthesis. To a N2-purged
solution of 19 (1 equiv.) in DCM (4mL per equiv. of 19) was added
K2CO3 (5 equiv.) and the corresponding amine (2.5 equiv.) (3 equiv. of
Et3N was added for HCl salts). AlMe3 (2.5 equiv.) was slowly added and the
reaction mixture was stirred at rt overnight. The reaction mixture was
carefully poured in 1M aq. HCl (100mL) and extracted with EtOAc
(100mL). The organic phase was washed with brine (100mL), dried over
MgSO4, filtered and concentrated to obtain the crude product as a brown
solid. The crude product was purified using flash column chromatography.
4.8.2.9. N-Butyl-3-(5-(cis-3-isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydro-
phthalazin-1-yl)-2-methoxyphenyl)propiolamide (21). This compound
was synthesized according to the general procedure using 19 (0.25 g,
0.63mmol) and butan-1-amine as the corresponding amine. Column
chromatography was performed using EtOAc/n-hept (gradient: 0–50%)
to obtain a white solid (182mg, 68%).
LC-MS (ESI): tR= 4.97min, area:> 98%, m/z: 422 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.94 (d, J=2.4 Hz, 1H), 7.90 (dd,
J=8.8, 2.4 Hz, 1H), 6.96 (t, J=8.1 Hz, 1H), 6.12–5.87 (m, 1H),
5.84–5.64 (m, 2H), 5.05 (hept, J=6.7 Hz, 1H), 3.95 (s, 3H), 3.38 (q,
J=6.9 Hz, 2H), 3.27 (dt, J=11.5, 5.7 Hz, 1H), 3.07–2.96 (m, 1H),
2.74 (t, J=5.8 Hz, 1H), 2.28–2.10 (m, 2H), 2.09–1.94 (m, 1H), 1.57 (p,
J=7.3 Hz, 2H), 1.41 (hept, J=7.6 Hz, 2H), 1.36–1.15 (m, 7H), 0.96
(t, J=7.3 Hz, 3H), 0.89 (t, J=6.9 Hz, 1H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.7, 153.4, 152.4, 132.0,
129.4, 129.1, 127.9, 126.0, 123.8, 110.9, 109.8, 87.3, 80.6, 56.1, 46.7,
43.2, 39.7, 34.7, 32.8, 31.4, 31.0, 23.0, 22.3, 20.6, 20.2, 20.1, 13.8.




(22). This compound was synthesized according to the general
procedure using 19 (0.20 g, 0.51mmol) and cyclopropylmethanamine
as the corresponding amine. Column chromatography was performed
using EtOAc/n-hept (gradient: 0–50%) to obtain a white solid (105mg,
49%).
LC-MS (ESI): tR= 4.80min, area: 98%, m/z: 420 [M+H]+.
1H NMR (500MHz, CDCl3): δ 8.01–7.85 (m, 2H), 6.95 (dd, J=8.9,
4.9 Hz, 1H), 6.35–6.18 (m, 1H), 5.82–5.61 (m, 2H), 5.03 (hept,
J=6.7 Hz, 1H), 3.94 (s, 3H), 3.49–3.16 (m, 3H), 3.04–2.94 (m, 1H),
2.72 (t, J=5.8 Hz, 1H), 2.26–2.09 (m, 2H), 2.07–1.92 (m, 1H), 1.32 (d,
J=6.6 Hz, 3H), 1.19 (d, J=6.7 Hz, 3H), 1.08–0.95 (m, 1H), 0.61–0.47
(m, 2H), 0.36–0.19 (m, 2H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.7, 153.3, 152.4, 132.0,
129.1, 128.0, 126.0, 123.8, 110.9, 109.8, 87.3, 80.8, 56.1, 48.3, 46.7,
44.8, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2, 10.5, 3.6.




compound was synthesized according to the general procedure using
19 (0.20 g, 0.51mmol) and cyclobutylmethanamine as the
corresponding amine. Column chromatography was performed using
EtOAc/n-hept (gradient: 0–50%) to obtain a white solid (115mg, 52%).
LC-MS (ESI): tR= 5.11min, area:> 98%, m/z: 434 [M+H]+.
1H NMR (500MHz, CDCl3): δ 8.05–7.84 (m, 2H), 6.96 (t,
J=9.3 Hz, 1H), 6.08 (q, J=6.5, 6.0 Hz, 1H), 5.83–5.63 (m, 2H), 5.04
(hept, J=6.6 Hz, 1H), 3.94 (s, 3H), 3.40 (dd, J=7.3, 5.9 Hz, 2H),
3.33–3.21 (m, 1H), 3.08–2.94 (m, 1H), 2.73 (q, J=6.0 Hz, 1H),
2.63–2.46 (m, J=7.7 Hz, 1H), 2.28–1.65 (m, 10H), 1.32 (d,
J=6.6 Hz, 3H), 1.20 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.7, 153.5, 152.4, 132.0,
129.1, 127.9, 126.0, 123.8, 110.9, 109.8, 87.3, 80.8, 56.1, 46.7, 45.2,
35.8, 34.7, 31.0, 25.7, 23.0, 22.3, 20.6, 20.2, 18.3.




compound was synthesized according to the general procedure using
19 (0.20 g, 0.51mmol) and 3-aminopropanenitrile as the corresponding
amine. Column chromatography was performed using EtOAc/n-hept
(gradient: 0–50%) to obtain a white solid (47mg, 22%).
LC-MS (ESI): tR= 4.35min, area:> 98%, m/z: 419 [M+H]+.
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1H NMR (500MHz, DMSO-d6): δ 9.12 (t, J=5.8 Hz, 1H), 8.04–7.93
(m, 2H), 7.21 (d, J=8.9 Hz, 1H), 5.74–5.57 (m, 2H), 4.88 (hept,
J=6.6 Hz, 1H), 3.91 (s, 3H), 3.46 (dt, J=11.6, 5.7 Hz, 1H), 3.39 (d,
J=6.3 Hz, 1H), 2.80 (t, J=6.4 Hz, 1H), 2.77–2.67 (m, 3H), 2.21–2.05
(m, 2H), 1.87–1.73 (m, 1H), 1.24 (d, J=6.5 Hz, 3H), 1.14 (d,
J=6.7 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.5, 161.8, 153.1, 153.0, 131.7,
130.1, 127.9, 126.3, 124.4, 119.7, 112.4, 109.3, 87.8, 80.8, 56.6, 46.2,
35.6, 34.2, 30.3, 22.8, 22.3, 20.9, 20.6, 17.8.




(25). This compound was synthesized according to the general
procedure using 19 (0.20 g, 0.51mmol) and azetidine-3-carbonitrile.
HCl as the corresponding amine. Column chromatography was
performed using EtOAc/n-hept (gradient: 0–50%) to obtain a white
solid (126mg, 58%).
LC-MS (ESI): tR= 4.59min, area:> 98%, m/z: 431 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.98–7.87 (m, 2H), 6.97 (d,
J=8.8 Hz, 1H), 5.83–5.63 (m, 2H), 5.04 (hept, J=6.6 Hz, 1H),
4.67–4.52 (m, 2H), 4.43 (t, J=9.7 Hz, 1H), 4.34 (dd, J=10.2, 6.2 Hz,
1H), 3.95 (s, 3H), 3.60 (tt, J=9.1, 6.2 Hz, 1H), 3.26 (dt, J=11.5,
5.8 Hz, 1H), 3.05–2.96 (m, 1H), 2.74 (t, J=6.0 Hz, 1H), 2.26–2.10 (m,
2H), 2.04–1.96 (m, 1H), 1.32 (d, J=6.6 Hz, 3H), 1.20 (d, J=6.7 Hz,
3H).
13C NMR (126MHz, CDCl3): δ 166.4, 162.0, 154.1, 152.2, 131.8,
129.7, 128.0, 126.0, 123.8, 119.0, 110.9, 109.3, 87.5, 83.5, 56.2, 53.4,
51.7, 46.7, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2, 17.5.




(26). This compound was synthesized according to the general
procedure using 19 (0.20 g, 0.51mmol) and (tetrahydrofuran-2-yl)
methanamine.HCl as the corresponding amine. Column
chromatography was performed using EtOAc/n-hept (gradient:
0–50%) to obtain a white solid (120mg, 53%).
LC-MS (ESI): tR= 4.46min, area:> 98%, m/z: 450 [M+H]+.
1H NMR (500MHz, CDCl3): δ 8.05–7.83 (m, 2H), 6.95 (t,
J=8.9 Hz, 1H), 6.43 (t, J=6.0 Hz, 1H), 5.83–5.61 (m, 2H), 5.03
(hept, J=6.7 Hz, 1H), 3.98–3.87 (m, 4H), 3.84 (dd, J=8.8, 6.9 Hz,
1H), 3.75 (q, J=7.8 Hz, 1H), 3.65–3.54 (m, 1H), 3.38 (q, J=6.5 Hz,
2H), 3.26 (dt, J=11.5, 5.7 Hz, 1H), 3.05–2.94 (m, 1H), 2.72 (t,
J=6.0 Hz, 1H), 2.61–2.50 (m, 1H), 2.25–2.05 (m, 3H), 2.04–1.93 (m,
1H), 1.71–1.59 (m, 1H), 1.31 (d, J=6.6 Hz, 3H), 1.19 (d, J=6.7 Hz,
3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.7, 153.7, 152.4, 132.0,
129.2, 127.9, 126.0, 123.8, 110.9, 109.7, 87.1, 81.2, 77.4, 77.1, 71.3,
67.8, 56.1, 46.7, 42.7, 38.9, 34.7, 30.9, 29.9, 23.0, 22.3, 20.6, 20.2.




compound was synthesized according to the general procedure using
19 (0.10 g, 0.25mmol) and morpholine as the corresponding amine.
Column chromatography was performed using EtOAc/n-hept (gradient:
0–50%) to obtain a white solid (56mg, 51%).
LC-MS (ESI): tR= 4.56min, area:> 98%, m/z: 436 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.96 (d, J=2.2 Hz, 1H), 7.91 (dd,
J=8.8, 2.3 Hz, 1H), 6.96 (d, J=8.9 Hz, 1H), 5.84–5.61 (m, 2H), 5.04
(hept, J=6.7 Hz, 1H), 3.94 (d, J=3.4 Hz, 5H), 3.82–3.75 (m, 2H),
3.72 (s, 4H), 3.27 (dt, J=11.5, 5.7 Hz, 1H), 3.07–2.94 (m, 1H), 2.74 (t,
J=6.0 Hz, 1H), 2.28–2.09 (m, 2H), 2.05–1.94 (m, 1H), 1.33 (d,
J=6.6 Hz, 3H), 1.21 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.9, 153.3, 152.3, 131.8,
129.3, 128.0, 126.0, 123.8, 110.9, 109.9, 87.3, 85.2, 67.0, 66.5, 56.1,
47.3, 46.7, 42.0, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2.




(11). This compound was synthesized according to the general
procedure using 19 (0.10 g, 0.25mmol) and 2-methyl-2H-1,2,3-
triazol-4-amine.HCl as the corresponding amine. Column
chromatography was performed using EtOAc/n-hept (gradient:
10–80%) to obtain a white solid (42mg, 37%).
LC-MS (ESI): tR= 4.54min, area:> 97%, m/z: 447 [M+H]+.
1H NMR (500MHz, CDCl3): δ 8.33 (s, 1H), 7.94 (s, 1H), 7.91 (d,
J=2.3 Hz, 1H), 7.86 (dd, J=8.8, 2.4 Hz, 1H), 6.90 (d, J=8.9 Hz,
1H), 5.78–5.57 (m, 2H), 4.98 (hept, J=6.7 Hz, 1H), 4.06 (s, 3H), 3.89
(s, 3H), 3.26–3.15 (m, 1H), 2.99–2.89 (m, 1H), 2.68 (t, J=6.0 Hz, 1H),
2.20–2.04 (m, 2H), 2.01–1.89 (m, 1H), 1.26 (d, J=6.6 Hz, 3H), 1.14
(d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 162.0, 152.2, 149.8, 143.2,
132.2, 129.7, 128.1, 126.0, 125.4, 123.8, 111.0, 109.2, 86.5, 83.4,
56.4, 46.8, 41.7, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2.




propiolamide (12). This compound was synthesized according to the
general procedure using 19 (0.10 g, 0.25mmol) and 4-(3-amino-1H-
pyrazol-1-yl)butanenitrile as the corresponding amine. Column
chromatography was performed using EtOAc/n-hept (gradient:
10–80%) to obtain a white solid (11mg, 9%).
LC-MS (ESI): tR= 4.49min, area:> 98%, m/z: 499 [M+H]+.
1H NMR (500MHz, CDCl3): δ 8.29 (s, 1H), 7.99 (d, J=2.3 Hz, 1H),
7.93 (dd, J=8.8, 2.3 Hz, 1H), 7.37 (s, 1H), 6.98 (d, J=8.8 Hz, 1H),
6.76 (s, 1H), 5.85–5.66 (m, 2H), 5.06 (hept, J=6.6 Hz, 1H), 4.20 (t,
J=6.2 Hz, 2H), 3.97 (s, 3H), 3.33–3.25 (m, 1H), 3.07–2.98 (m, 1H),
2.76 (t, J=5.9 Hz, 1H), 2.35 (t, J=6.8 Hz, 2H), 2.28–2.13 (m, 4H),
2.08–1.97 (m, 1H), 1.35 (d, J=6.6 Hz, 3H), 1.23 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 162.0, 152.3, 150.0, 132.2,
131.0, 129.5, 128.0, 126.0, 123.8, 118.6, 111.0, 109.4, 98.2, 87.0,
82.6, 56.1, 49.9, 46.8, 34.7, 31.0, 25.9, 23.0, 22.3, 20.6, 20.2, 14.5.




compound was synthesized according to the general procedure using
19 (0.20 g, 0.51mmol) and furfurylamine as the corresponding amine.
Column chromatography was performed using EtOAc/n-hept (gradient:
0–50%) to obtain a white solid (112mg, 50%).
LC-MS (ESI): tR= 4.78min, area:> 98%, m/z: 446 [M+H]+.
1H NMR (500MHz, CDCl3): δ 8.02–7.85 (m, 2H), 7.39 (d,
J=1.8 Hz, 1H), 7.01–6.91 (m, 1H), 6.42 (d, J=6.8 Hz, 1H), 6.38–6.27
(m, 2H), 5.85–5.61 (m, 2H), 5.05 (p, J=6.6 Hz, 1H), 4.55 (d,
J=5.6 Hz, 2H), 3.93 (s, 3H), 3.26 (dt, J=11.5, 5.7 Hz, 1H), 3.11–2.91
(m, 1H), 2.73 (t, J=6.0 Hz, 1H), 2.27–2.10 (m, 2H), 2.04–1.95 (m,
1H), 1.33 (d, J=6.6 Hz, 3H), 1.20 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.8, 153.1, 152.4, 150.3,
142.5, 132.0, 129.3, 127.9, 126.0, 123.8, 110.9, 110.6, 109.6, 108.1,
86.8, 81.5, 56.1, 46.7, 36.7, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2.
HRMS (ESI): m/z: [M+H]+ calcd. for C26H28N3O4 446.2074, found
446.2055.




(29). This compound was synthesized according to the general
procedure using 19 (0.20 g, 0.51mmol) and (5-methylfuran-2-yl)
methanamine as the corresponding amine. Column chromatography
was performed using EtOAc/n-hept (gradient: 0–50%) to obtain a white
solid (112mg, 48%).
LC-MS (ESI): tR= 4.96min, area:> 98%, m/z: 460 [M+H]+.
1H NMR (500MHz, DMSO-d6): δ 9.21 (t, J=5.8 Hz, 1H), 8.02–7.93
(m, 2H), 7.20 (d, J=8.8 Hz, 1H), 6.15 (d, J=3.0 Hz, 1H), 6.03–5.97
(m, 1H), 5.74–5.58 (m, 2H), 4.87 (hept, J=6.6 Hz, 1H), 4.27 (d,
J=5.7 Hz, 2H), 3.90 (s, 3H), 3.44 (dt, J=11.6, 5.8 Hz, 1H), 2.80 (t,
J=6.0 Hz, 1H), 2.78–2.69 (m, 1H), 2.23 (d, J=1.0 Hz, 3H), 2.19–2.04
(m, 2H), 1.85–1.74 (m, 1H), 1.23 (d, J=6.5 Hz, 3H), 1.14 (d,
J=6.8 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.5, 161.8, 153.1, 152.6, 151.3,
145.0, 131.6, 130.0, 127.9, 126.3, 124.4, 112.3, 109.5, 108.7, 106.9,
88.0, 80.7, 56.6, 46.2, 36.1, 34.2, 30.3, 22.9, 22.3, 20.9, 20.6, 13.8.




compound was synthesized according to the general procedure using
19 (0.15 g, 0.38mmol) and thiophen-2-ylmethanamine as the
corresponding amine. Column chromatography was performed using
EtOAc/n-hept (gradient: 0–50%) to obtain a white solid (76mg, 43%).
LC-MS (ESI): tR= 5.00min, area:> 98%, m/z: 462 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.92 (d, J=2.4 Hz, 1H), 7.89 (dd,
J=8.8, 2.4 Hz, 1H), 7.27–7.23 (m, 1H), 7.08–7.02 (m, 1H), 6.97 (dd,
J=5.2, 3.4 Hz, 1H), 6.94 (d, J=8.9 Hz, 1H), 6.54 (t, J=5.8 Hz, 1H),
5.82–5.64 (m, 2H), 5.03 (p, J=6.6 Hz, 1H), 4.71 (d, J=5.7 Hz, 2H),
3.91 (s, 3H), 3.25 (dt, J=11.4, 5.7 Hz, 1H), 3.04–2.95 (m, 1H), 2.71 (t,
J=6.0 Hz, 1H), 2.24–2.10 (m, 2H), 2.04–1.93 (m, 1H), 1.32 (d,
J=6.5 Hz, 3H), 1.19 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.8, 153.0, 152.4, 139.6,
132.0, 129.3, 127.9, 127.0, 126.7, 126.0, 125.6, 123.8, 110.9, 109.6,
86.9, 81.6, 56.1, 46.7, 38.5, 34.7, 30.9, 23.0, 22.3, 20.6, 20.2.




(31). This compound was synthesized according to the general
procedure using 19 (0.15 g, 0.38mmol) and 2-(thiophen-2-yl)
ethanamine as the corresponding amine. Column chromatography
was performed using EtOAc/n-hept (gradient: 0–50%) to obtain a
white solid (87mg, 48%).
LC-MS (ESI): tR= 5.09min, area:> 98%, m/z: 476 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.92 (d, J=2.4 Hz, 1H), 7.88 (dd,
J=8.8, 2.4 Hz, 1H), 7.21–7.14 (m, 1H), 6.99–6.91 (m, 2H), 6.88 (dd,
J=3.3, 1.2 Hz, 1H), 6.36 (t, J=6.1 Hz, 1H), 5.81–5.62 (m, 2H), 5.04
(p, J=6.6 Hz, 1H), 3.91 (s, 3H), 3.64 (q, J=6.6 Hz, 2H), 3.25 (dt,
J=11.5, 5.7 Hz, 1H), 3.10 (t, J=6.8 Hz, 2H), 3.05–2.95 (m, 1H), 2.72
(q, J=7.7, 5.9 Hz, 1H), 2.25–1.97 (m, 3H), 1.32 (dd, J=6.6, 2.6 Hz,
3H), 1.20 (dd, J=6.7, 2.9 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.8, 153.4, 152.4, 140.9,
132.0, 129.2, 127.9, 127.1, 126.0, 125.5, 124.1, 123.8, 110.9, 109.7,
87.2, 81.1, 56.1, 46.7, 41.3, 34.7, 30.9, 26.9, 23.0, 22.3, 20.6, 20.2.




(32). This compound was synthesized according to the general
procedure using 19 (0.20 g, 0.51mmol) and (2-methylthiazol-4-yl)
methanamine.2HCl as the corresponding amine. Column
chromatography was performed using EtOAc/n-hept (gradient:
0–50%) to obtain a white solid (142mg, 59%).
LC-MS (ESI): tR= 4.57min, area:> 97%, m/z: 477 [M+H]+.
1H NMR (500MHz, DMSO-d6): δ 9.29 (t, J=6.0 Hz, 1H), 8.03–7.91
(m, 2H), 7.25 (d, J=0.9 Hz, 1H), 7.21 (d, J=8.8 Hz, 1H), 5.73–5.57
(m, 2H), 4.88 (p, J=6.6 Hz, 1H), 4.37 (dd, J=6.0, 1.0 Hz, 2H), 3.91
(s, 3H), 3.44 (dt, J=11.7, 5.8 Hz, 1H), 2.81 (t, J=6.1 Hz, 1H),
2.77–2.68 (m, 1H), 2.63 (s, 3H), 2.21–2.05 (m, 2H), 1.87–1.71 (m, 1H),
1.24 (d, J=6.6 Hz, 3H), 1.14 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.5, 166.0, 161.8, 153.1, 152.9,
152.7, 131.6, 130.0, 127.9, 126.3, 124.4, 115.6, 112.4, 109.6, 88.1,
80.6, 56.6, 46.2, 34.2, 30.3, 22.9, 22.3, 20.9, 20.6, 19.2.




compound was synthesized according to the general procedure using
19 (0.15 g, 0.38mmol) and 2-(thiazol-2-yl)ethanamine as the
corresponding amine. Column chromatography was performed using
EtOAc/n-hept (gradient: 0–50%) to obtain a white solid (81mg, 45%).
LC-MS (ESI): tR= 4.59min, area:> 98%, m/z: 477 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.93 (d, J=2.3 Hz, 1H), 7.89 (dd,
J=8.8, 2.4 Hz, 1H), 7.74 (d, J=3.3 Hz, 1H), 6.94 (d, J=8.8 Hz, 1H),
6.91 (t, J=6.1 Hz, 1H), 5.83–5.64 (m, 2H), 5.05 (hept, J=6.6 Hz,
1H), 3.94 (s, 3H), 3.85 (q, J=6.1 Hz, 2H), 3.34–3.23 (m, 3H),
3.06–2.96 (m, 1H), 2.73 (t, J=6.0 Hz, 1H), 2.27–2.11 (m, 2H),
2.06–1.97 (m, 1H), 1.33 (d, J=6.7 Hz, 3H), 1.21 (d, J=6.6 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 167.7, 166.4, 161.8, 153.4, 152.4,
142.4, 132.0, 129.2, 127.9, 126.0, 123.8, 119.0, 110.9, 109.8, 87.2,
81.2, 56.1, 46.7, 38.7, 34.7, 32.3, 31.0, 23.0, 22.3, 20.6, 20.2.




propiolamide (34). This compound was synthesized according to the
general procedure using 19 (0.10 g, 0.25mmol) and (2,4-
dimethylthiazol-5-yl)methanamine as the corresponding amine.
Column chromatography was performed using EtOAc/n-hept
(gradient: 10–80%) to obtain a white solid (36mg, 29%).
LC-MS (ESI): tR= 4.39min, area:> 98%, m/z: 491 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.93 (d, J=2.3 Hz, 1H), 7.90 (dd,
J=8.8, 2.4 Hz, 1H), 6.95 (d, J=8.8 Hz, 1H), 6.27 (t, J=5.7 Hz, 1H),
5.83–5.76 (m, 1H), 5.72–5.64 (m, 1H), 5.05 (p, J=6.7 Hz, 1H), 4.61
(d, J=5.6 Hz, 2H), 3.94 (s, 3H), 3.30–3.23 (m, 1H), 3.07–2.97 (m, 1H),
2.74 (t, J=6.1 Hz, 1H), 2.66 (s, 3H), 2.41 (s, 3H), 2.26–2.10 (m, 2H),
2.07–1.95 (m, 1H), 1.33 (d, J=6.6 Hz, 3H), 1.21 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 164.5, 161.8, 153.0, 152.3,
149.7, 132.1, 129.4, 128.0, 126.1, 126.0, 123.8, 110.9, 109.5, 86.6,
81.9, 56.1, 46.7, 35.3, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2, 19.1, 14.9.




propiolamide (35). This compound was synthesized according to the
general procedure using 19 (0.15 g, 0.38mmol) and (1-methyl-1H-
pyrazol-4-yl)methanamine as the corresponding amine. Column
chromatography was performed using EtOAc/n-hept (gradient:
10–80%) to obtain a white solid (73mg, 42%).
LC-MS (ESI): tR= 4.37min, area:> 98%, m/z: 460 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.89 (d, J=2.3 Hz, 1H), 7.86 (dd,
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J=8.8, 2.4 Hz, 1H), 7.40 (d, J=15.1 Hz, 2H), 6.97–6.89 (m, 1H), 6.61
(t, J=5.7 Hz, 1H), 5.79–5.58 (m, 2H), 5.00 (p, J=6.7 Hz, 1H), 4.36
(d, J=5.7 Hz, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.27–3.17 (m, 1H),
3.02–2.91 (m, 1H), 2.69 (t, J=5.9 Hz, 1H), 2.23–2.06 (m, 2H),
2.01–1.90 (m, 1H), 1.29 (d, J=6.6 Hz, 3H), 1.17 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.7, 153.2, 152.4, 138.8,
131.9, 129.7, 129.2, 127.9, 126.0, 123.8, 117.7, 110.9, 109.7, 87.1,
81.2, 56.0, 46.7, 38.9, 34.6, 34.3, 30.9, 22.9, 22.2, 20.6, 20.2.




(36). This compound was synthesized according to the general
procedure using 19 (0.15 g, 0.38mmol) and 3-(1H-imidazol-1-yl)
propan-1-amine as the corresponding amine. Column chromatography
was performed using EtOAc/n-hept (gradient: 10–100%)to obtain a
white solid (101mg, 56%).
LC-MS (ESI): tR= 3.59min, area:> 98%, m/z: 474 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.86 (d, J=2.4 Hz, 1H), 7.82 (dd,
J=8.8, 2.3 Hz, 1H), 7.45 (s, 1H), 7.08 (t, J=6.2 Hz, 1H), 7.01 (s, 1H),
6.93–6.84 (m, 2H), 5.75–5.54 (m, 2H), 4.96 (p, J=6.7 Hz, 1H), 3.97 (t,
J=6.9 Hz, 2H), 3.85 (s, 3H), 3.27 (q, J=6.5 Hz, 2H), 3.23–3.14 (m,
1H), 2.97–2.86 (m, 1H), 2.65 (t, J=6.0 Hz, 1H), 2.19–2.03 (m, 2H),
2.03–1.97 (m, 2H), 1.96–1.86 (m, 1H), 1.24 (d, J=6.6 Hz, 3H),
1.17–1.09 (m, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.7, 153.9, 152.4, 137.2,
132.0, 129.4, 129.3, 128.0, 126.0, 123.8, 118.9, 111.0, 109.7, 87.1,
81.3, 56.1, 46.7, 44.4, 36.9, 34.7, 30.9, 30.9, 23.0, 22.3, 20.6, 20.2.
HRMS (ESI): m/z: [M+H]+ calcd. for C27H32N5O3 474.2500, found
474.2496.
4.8.2.27. N-Benzyl-3-(5-(cis-3-isopropyl-4-oxo-3,4,4a,5,8,8a-hexahydro-
phthalazin-1-yl)-2-methoxyphenyl)propiolamide (37). This compound
was synthesized according to the general procedure using 19 (0.10 g,
0.25mmol) and phenylmethanamine as the corresponding amine.
Column chromatography was performed using EtOAc/n-hept
(gradient: 0–50%) to obtain a white solid (80mg, 69%).
LC-MS (ESI): tR= 4.93min, area:> 98%, m/z: 456 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.94 (d, J=2.2 Hz, 1H), 7.90 (dd,
J=8.8, 2.3 Hz, 1H), 7.41–7.29 (m, 5H), 6.94 (d, J=8.8 Hz, 1H), 6.41
(t, J=5.8 Hz, 1H), 5.83–5.63 (m, 2H), 5.04 (hept, J=6.7 Hz, 1H),
4.56 (d, J=5.7 Hz, 2H), 3.92 (s, 3H), 3.26 (dt, J=11.5, 5.7 Hz, 1H),
3.06–2.95 (m, 1H), 2.72 (t, J=5.9 Hz, 1H), 2.26–2.10 (m, 2H),
2.07–1.95 (m, 1H), 1.33 (d, J=6.5 Hz, 3H), 1.20 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.8, 153.3, 152.4, 137.3,
132.0, 129.2, 128.8, 128.1, 127.9, 127.8, 126.0, 123.8, 110.9, 109.7,
87.0, 81.4, 56.1, 46.7, 44.0, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2.




compound was synthesized according to the general procedure using
19 (0.20 g, 0.51mmol) and pyridin-3-ylmethanamine.HCl as the
corresponding amine. Column chromatography was performed using
EtOAc/n-hept (gradient: 0–50%) to obtain a white solid (142mg, 61%).
LC-MS (ESI): tR= 3.72min, area:> 98%, m/z: 457 [M+H]+.
1H NMR (500MHz, DMSO-d6): δ 9.37 (t, J=6.1 Hz, 1H), 8.52 (d,
J=2.2 Hz, 1H), 8.48 (dd, J=4.7, 1.7 Hz, 1H), 8.02–7.92 (m, 2H), 7.70
(dt, J=7.8, 2.0 Hz, 1H), 7.43–7.33 (m, 1H), 7.20 (d, J=8.8 Hz, 1H),
5.75–5.56 (m, 2H), 4.87 (hept, J=6.6 Hz, 1H), 4.37 (d, J=6.0 Hz,
2H), 3.90 (s, 3H), 3.44 (dt, J=11.5, 5.7 Hz, 1H), 2.80 (t, J=6.1 Hz,
1H), 2.78–2.68 (m, 1H), 2.21–2.05 (m, 2H), 1.86–1.72 (m, 1H), 1.23 (d,
J=6.7 Hz, 3H), 1.13 (d, J=6.8 Hz, 3H).
13C NMR (126MHz, DMSO-d6): δ 166.5, 161.8, 153.1, 152.9, 149.4,
148.8, 135.8, 134.6, 131.6, 130.1, 127.9, 126.3, 124.4, 124.0, 112.3,
109.4, 87.9, 80.8, 56.6, 46.2, 40.6, 34.2, 30.3, 22.8, 22.3, 20.9, 20.5.




compound was synthesized according to the general procedure using
19 (0.10 g, 0.25mmol) and pyridin-4-ylmethanamine as the
corresponding amine. Column chromatography was performed using
EtOAc/n-hept (gradient: 0–50%) to obtain a white solid (67mg, 58%).
LC-MS (ESI): tR= 3.64min, area:> 98%, m/z: 457 [M+H]+.
1H NMR (500MHz, CDCl3): δ 8.62 (s, 2H), 7.95 (d, J=2.3 Hz, 1H),
7.91 (dd, J=8.8, 2.4 Hz, 1H), 7.29 (s, 2H), 6.98–6.90 (m, 1H), 6.67 (t,
J=6.3 Hz, 1H), 5.83–5.64 (m, 2H), 5.05 (hept, J=6.7 Hz, 1H), 4.58
(d, J=6.1 Hz, 2H), 3.94 (s, 3H), 3.26 (dq, J=11.9, 5.9 Hz, 1H),
3.06–2.96 (m, 1H), 2.74 (t, J=6.0 Hz, 1H), 2.26–2.10 (m, 2H),
2.06–1.99 (m, 1H), 1.33 (d, J=6.6 Hz, 3H), 1.21 (d, J=6.6 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.8, 153.6, 152.3, 149.9,
146.6, 132.1, 129.7, 129.5, 128.0, 126.0, 123.8, 111.0, 109.4, 86.6,
82.2, 56.1, 46.7, 42.6, 34.7, 31.0, 23.0, 22.3, 20.6, 20.2.




compound was synthesized according to the general procedure using
19 (0.20 g, 0.51mmol) and 3-methoxyaniline as the corresponding
amine. Column chromatography was performed using EtOAc/n-hept
(gradient: 0–50%) to obtain a white solid (98mg, 41%).
LC-MS (ESI): tR= 5.10min, area:> 98%, m/z: 472 [M+H]+.
1H NMR (500MHz, CDCl3): δ 7.97 (d, J=2.6 Hz, 2H), 7.92 (dd,
J=8.8, 2.3 Hz, 1H), 7.33 (t, J=2.3 Hz, 1H), 7.24 (t, J=8.1 Hz, 1H),
7.09 (dd, J=7.9, 1.9 Hz, 1H), 6.97 (d, J=8.9 Hz, 1H), 6.71 (dd,
J=8.2, 2.4 Hz, 1H), 5.85–5.63 (m, 2H), 5.06 (hept, J=6.6 Hz, 1H),
3.96 (s, 3H), 3.82 (s, 3H), 3.28 (dt, J=11.6, 5.7 Hz, 1H), 3.07–2.97 (m,
1H), 2.74 (t, J=6.0 Hz, 1H), 2.27–2.12 (m, 2H), 2.05–1.96 (m, 1H),
1.34 (d, J=6.6 Hz, 3H), 1.22 (d, J=6.7 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.9, 160.1, 152.4, 151.0,
138.6, 132.1, 129.8, 129.5, 128.0, 126.0, 123.8, 112.1, 111.0, 110.6,
109.5, 105.8, 87.7, 82.0, 56.1, 55.4, 46.8, 34.7, 31.0, 23.0, 22.3, 20.6,
20.2.




compound was synthesized according to the general procedure using
19 (0.20 g, 0.51mmol) and 2-(2-fluorophenyl)ethanamine as the
corresponding amine. Column chromatography was performed using
EtOAc/n-hept (gradient: 0–50%) to obtain a white solid (110mg, 45%).
LC-MS (ESI): tR= 5.07min, area:> 98%, m/z: 488 [M+H]+.
1H NMR (500MHz, CDCl3): δ 8.00–7.84 (m, 2H), 7.27–7.16 (m,
2H), 7.14–6.99 (m, 2H), 6.95 (dd, J=13.4, 8.9 Hz, 1H), 6.31 (q,
J=7.0 Hz, 1H), 5.85–5.61 (m, 2H), 5.04 (p, J=6.7 Hz, 1H), 3.91 (s,
3H), 3.62 (q, J=6.8 Hz, 2H), 3.27 (tt, J=11.5, 5.7 Hz, 1H), 3.07–2.87
(m, 3H), 2.73 (dt, J=11.9, 5.9 Hz, 1H), 2.28–2.09 (m, 2H), 2.04–1.94
(m, 1H), 1.32 (dd, J=6.6, 3.4 Hz, 3H), 1.20 (dd, J=6.9, 4.2 Hz, 3H).
13C NMR (126MHz, CDCl3): δ 166.4, 161.8, 153.5, 152.4, 132.0,
131.1, 129.2, 128.4, 127.9, 126.0, 125.4, 124.3, 123.8, 115.5, 115.3,
110.9, 109.8, 87.2, 81.0, 56.1, 46.7, 39.9, 34.7, 30.9, 29.0, 23.0, 22.3,
20.6, 20.2.
HRMS (ESI): m/z: [M+H]+ calcd. for C29H31FN3O3 488.2344,
found 488.2341.
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